FDMT 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase I/II clinical trial for the treatment of fabry disease. It also focuses on developing two investigational new drug candidates, which include 4D-150 for the treatment of wet age-related macular degeneration; and 4D-710 for the treatment of cystic fibrosis lung disease. The company was founded in 2013 and is headquartered in Emeryville, California.

$26.36  -1.21 (-4.39%)
As of 05/13/2021 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/11/2020
Outstanding shares:  26,694,379
Average volume:  106,772
Market cap:   $801,098,314
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    35104E100
ISIN:        US35104E1001
Sedol:      BKLXFX5
Valuation   (See tab for details)
PE ratio:   -21.18
PB ratio:   3.03
PS ratio:   100.14
Return on equity:   -14.30%
Net income %:   -3,481.67%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy